Damien de Chillaz

Damien de Chillaz began their work experience as an Analyst Intern at McKinsey & Company in 2001. Damien then worked at Societe Generale Corporate and Investment Banking (SGCIB) in various roles, including Vice President of Equity Derivatives and Head of Market Risk Advisory for the Americas. During their time at SGCIB, Damien managed the turnaround of SG Constellation and authored an article on self-financing B&C shares. In 2016, they joined Capgemini as the Head of Blockchain & B2B Platforms, where they focused on business development in areas such as KYC and supply chains. Damien co-designed solutions with clients, leveraging technologies such as Distributed Ledger Technology (DLT), Intelligent Automation, and Artificial Intelligence. Damien also served as the Vice President of Strategic & Acquisition Finance during their tenure at SGCIB. Currently, Damien is the CEO of KatalX, a Trusted Supply Chain Visibility Platform, where they aim to provide end-to-end supply chain control for shippers while collaborating with 3PLs, carriers, and customers.

Damien de Chillaz's education history can be summarized as follows:

From 1998 to 2001, Damien attended École Polytechnique, though their degree name and field of study are not specified.

In 2001, Damien also attended École des Ponts ParisTech, where they obtained a Master of Engineering degree. No specific field of study is mentioned.

During the same year, from 1998 to 1999, Damien completed their Military Service at the École Spéciale Militaire de Saint-Cyr.

In 2002, Damien pursued a Master's degree in Corporate Finance and Capital Markets at Sciences Po, which they completed in 2003.

Damien's high school education is not provided, but it is mentioned that they attended Lycée Sainte-Geneviève.

Additionally, Damien has obtained several certifications. In 2007, they acquired the Series 7 certification from FINRA. In 2015, they completed an Executive Education program in High Impact Leadership at Columbia Business School. Furthermore, they became a member of FrenchFounders in 2019 and gained membership in Pharma.Aero, BioNJ, and France Biotech through KatalX in 2022.